Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The platelet-dependent thrombin generation pathway refers to the process by which platelets facilitate and amplify the production of thrombin, a key enzyme in blood coagulation. This pathway is central to both normal hemostasis (stopping bleeding) and pathological thrombosis (clot formation leading to disease). Upon activation, platelets expose phosphatidylserine on their outer membrane leaflet, providing a catalytic surface for assembly of coagulation complexes such as tenase (factors VIIIa/IXa) and prothrombinase (factors Va/Xa), which are essential for efficient conversion of prothrombin to thrombin. The process is highly dependent on platelet-binding proteins as well as changes in lipid composition; both are necessary for optimal regulation but neither alone is sufficient. Dysregulation can lead either to excessive bleeding (if impaired) or pathological thrombosis such as myocardial infarction or stroke (if overactive). Platelet TLR2/TLR4 can mediate responses linking inflammation with enhanced procoagulant activity.
Inhibition of platelet activation or coagulation factors
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platelet-dependent thrombin generation pathway (None).